ReviewOncotarget2015
The biology and treatment of oligometastatic cancer.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
173 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Bibliometric analysis of stereotactic ablative radiotherapy for oligometastases.Frontiers in medicine · 2026Pooled it
- Stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (OMOC): a systematic review and meta-analysis of clinical outcomes and toxicity profiles.Frontiers in pharmacology · 2025Pooled it
- Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Emerging Indications for Interventional Oncology: A Comprehensive Systematic Review of Image-Guided Thermal Ablation for Metastatic Non-cervical Lymph Node Disease.Current oncology reports · 2024Pooled it
- Magnetic resonance-guided focused ultrasound versus percutaneous thermal ablation in local control of bone oligometastases: a systematic review and meta-analysis.La Radiologia medica · 2024Pooled it
- Stereotactic body radiotherapy (SBRT) in metachronous oligometastatic prostate cancer: a systematic review and meta-analysis on the current prospective evidence.The British journal of radiology · 2020Pooled it
- A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?World journal of urology · 2019Pooled it
- Single-arm multicenter phase II study on aggressive local consolidative therapy in combination with systemic chemotherapy for stage IV non-small cell lung carcinoma with oligometastases: CURE-OLIGO (TORG1529).Radiation oncology (London, England) · 2025Trial
- CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.The Prostate · 2021Trial
- Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.BMC cancer · 2019Trial
- Pre-progression Surgery Added to Imatinib is Associated with Prolonged Survival in Oligometastatic GIST: A Covariate-Matched Study.Annals of surgical oncology · 2026Article
- Surviving Cancer, Lacking Support: The Hidden Burden of Modern Radiation Oncology in the Treatment of Oligometastatic Disease.Cancers · 2026Review
- Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery.World journal of surgery · 2026Review
- Oligometastatic disease in pancreatic cancer: is there a role for curative-intent surgery? A narrative review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Review
- Factors determining survival in oligometastatic breast cancer in a retrospective cohort study from a low and middle income country.Scientific reports · 2026Article
- Surgical management of metastatic squamous cell carcinoma of the bladder: a case report and review of the literature.Frontiers in oncology · 2026Article
- A comprehensive review of de novo oligometastatic breast cancer: Current treatment options, surgical outcomes, and systemic therapy.Northern clinics of Istanbul · 2026Review
- Feedback regulation between histone H3 lysine 18 lactylation and TROP2-mediated glycolysis drives metastatic progression of colorectal cancer.Clinical and translational medicine · 2026Article
- Article
113 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clinical reports of limited and treatable cancer metastases, a disease state that exists in a transitional zone between localized and widespread systemic disease, were noted on occasion historically and are now termed oligometastasis. The ramification of a diagnosis of oligometastasis is a change in treatment paradigm, i.e. if the primary cancer site (if still present) is controlled, or resected, and the metastatic sites are ablated (surgically or with radiation), a prolonged disease-free interval, and perhaps even cure, may be achieved. Contemporary molecular diagnostics are edging closer to being able to determine where an individual metastatic deposit is within the continuum of malignancy. Preclinical models are on the outset of laying the groundwork for understanding the oligometastatic state. Meanwhile, in the clinic, patients are increasingly being designated as having oligometastatic disease and being treated owing to improved diagnostic imaging, novel treatment options with the potential to provide either direct or bridging therapy, and progressively broad definitions of oligometastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.